Endophthalmitis After Intravitreal Injections

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-29231-1_7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates.

  2015cited by this paper
• Endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications

  2015cited by this paper
• Ocular inflammation associated with antivascular endothelial growth factor treatment

  2015cited by this paper
• Effect of a Strict 'No-Talking' Policy During Intravitreal Injection on Post-Injection Endophthalmitis.

  2015cited by this paper
• Povidone-iodine for endophthalmitis prophylaxis.

  2014cited by this paper
• The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection.

  2014cited by this paper
• Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics.

  2013cited by this paper
• Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results.

  2013cited by this paper
• PARS PLANA VITRECTOMY IN THE MANAGEMENT OF PATIENTS DIAGNOSED WITH ENDOPHTHALMITIS FOLLOWING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION

  2013cited by this paper
• Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.

  2013cited by this paper
• Associated factors and treatment outcome of presumed noninfectious endophthalmitis occurring after intravitreal triamcinolone acetonide injection

  2013cited by this paper
• Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

  2013cited by this paper
• POVIDONE–IODINE CONTACT TIME AND LID SPECULUM USE DURING INTRAVITREAL INJECTION

  2013cited by this paper
• Is the use of topical antibiotics for intravitreal injections the standard of care or are we better off without antibiotics?

  2013cited by this paper
• Avastin doesn't blind people, people blind people.

  2012cited by this paper
• Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

  2012cited by this paper
• Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.

  2012cited by this paper
• Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes

  2012cited by this paper
• An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab.

  2012cited by this paper
• Bacterial dispersal associated with speech in the setting of intravitreous injections.

  2011cited by this paper
• Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

  2011cited by this paper
• ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS: A Six-Year Experience at a University Referral Center

  2011cited by this paper
• Endophthalmitis after intravitreal injection: prevention and management.

  2011cited by this paper
• Endophthalmitis after intravitreal injections: should the use of face masks be the standard of care?

  2011cited by this paper
• Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.

  2011cited by this paper
• META-ANALYSIS OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS: Causative Organisms and Possible Prevention Strategies

  2011cited by this paper
• Use of retinal procedures in medicare beneficiaries from 1997 to 2007.

  2010cited by this paper
• Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• Endophthalmitis after intravitreal injections

  2009cited by this paper
• Anatomic and visual outcomes of noninfectious endophthalmitis after intravitreal triamcinolone.

  2008cited by this paper
• Risk Factors Leading to Enucleation or Evisceration in Endophthalmitis

  2007cited by this paper

• Novel Combined Lidocaine/Povidone Iodine Delivery System for Preintravitreal Injection

  2022cites this paper
• Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-Related Macular Degeneration

  2021cites this paper
• Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery

  2017cites this paper
• Current advances in the treatment of neovascular age-related macular degeneration

  2017cites this paper
• Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye

  2016cites this paper
• Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics

  2015cites this paper
• Intravitreal Injection--Technique and Safety.

  2015cites this paper
• Clinical Ophthalmology Dovepress

  year unknowncites this paper